Biosimilar drugs have been touted as one strategy to help curb the runaway costs of biologics that have advanced the treatment of illness such as rheumatoid arthritis and many cancers. A new study finds biosimilars could cut health care spending in the United States by $54 billion over the next decade. The savings are about 20 percent larger than a similar, widely cited analysis done three years ago by the same researchers.